RN(NP) Info and Updates

We do our best to keep you up to date on new information as it is released. However, it is your responsibility to check this page often to make sure you are aware of important updates and changes to your practice.


  • October 4, 2021 - Discontinuation of Routine Lead Patient Shielding in Diagnostic Imaging

    Professional bodies around the world, including the Canadian Association of Medical Radiation Technologists (CAMRT) and Canadian Association of Radiologists (CAR), have released position statements advocating for the discontinuation of shielding for patients during x-ray examinations. Shared Health staff providing diagnostic imaging appointments will no longer use patient shielding as part of their routine practice. Staff will continue all other practices as normal. Shielding will remain in DI departments and must still be available for use if requested by the patient or caregiver. Click here for more details.

  • September 29, 2021 - Narcotic and Controlled Drug Prescriptions for Personal Care Home Residents

    Effective October 1, 2021, verbal orders from physicians and RN(NP)s for narcotics and controlled drugs that fall under the Health Canada Controlled Drugs and Substances Act (CDSA) may be accepted by pharmacists for residents of a personal care home (PCH) only. This exemption does NOT apply to patients who are not a resident of a personal care home at the time the verbal order is given. Of note, this exemption was originally initiated in conjunction with the Health Canada Section 56(1) class exemption dated March 19, 2020, and approved jointly by the three health regulatory authorities (College of Physicians and Surgeons of Manitoba, College of Registered Nurses of Manitoba, and College of Pharmacists of Manitoba) for implementation on April 7, 2020, with an expiry date of September 30, 2021.

    This temporary exemption has once again been jointly approved, remaining in effect during the COVID19 pandemic and may not extend beyond September 30, 2026. Click here to read more.

  • September 2021 - Safety Review of Gadolinium-Based Contrast Agents (GBCAs) - Gadolinium-based contrast agents (GBCAs) are authorized for sale in Canada to make certain body tissues easier to see during a magnetic resonance imaging (MRI) or a magnetic resonance angiography (MRA) scan. Health Canada reviewed the potential risks of birth defects (congenital anomalies), death of the unborn baby (stillbirth) and baby’s death in the first month of life (neonatal death) with the use of GBCAs during pregnancy. Health Canada’s review of the available information found no link between the use of GBCAs during pregnancy and the risk of congenital anomalies. However, at this time, there is not enough information to rule out a link. As a precaution, given the potential for serious harm to unborn babies (fetuses) and infants, Health Canada will work with the manufacturers of GBCAs to include the potential risks of stillbirth and neonatal death in their Canadian Product Monographs (CPMs) to raise awareness among healthcare professionals and encourage reporting of these potential safety issues. Click here to read more. 
  • September 2021 - Urine Culture Investigations – Reminder to Include Clinical Justification - Shared Health Diagnostic Services (Lab) have established new testing protocols to reflect best practice and testing algorithms. The Clinical Microbiology Requisition has been revised to enable these changes. Shared Health is reminding all practitioners that when completing a Clinical Microbiology requisition they should consult the Clinical Microbiology Requisition – Visual Aide (see linked PDF below) to ensure required information is included on the requisition. The omission of required information will result in testing delays or sample rejection and the necessity for recollection of a new sample. Click here to read more.
  • February 2021 - Check out the CRNM Code of Ethics Application document on the Distribution of Drugs as Samples: Click here
  • December 2020 - Improve opioid prescribing through the Online Opioid Self-Assessment Program. This program is easily accessible, highly interactive and uses assessment as a technique for knowledge exchange and guideline implementation using the most up-to-date tools and resources. In order to facilitate active learning, a variety of techniques are employed, including videos, case presentations and an assortment of question types to keep you engaged and apply it in practice.  This course is based on the updated 2017 Canadian Opioid Guideline. Free availability of the course ends March 2021.  
  • September 4, 2020 - Nurse Practitioner Regulation Framework Implementation Plan Project Underway - The Nurse Practitioner Regulation Framework Implementation Plan Project (NPR-FIPP) is a multi-year initiative commissioned by the Canadian Council of Registered Nurse Regulators (CCRNR). The NPR-FIPP looks at implementing the six basic elements of a model for NP regulation in Canada, including entry-level NP education programs preparing RNs to meet NP entry-level competencies across the life span and diverse practice settings, and a new, single entry-level examination for all NPs across the country. It also includes developing a common set of standards and principles surrounding standards of practice, continuing competence, registration/renewal, and re-entry to practice. You can stay up to date on the NPR-FIPP at the CCRNR website.
  • April 17, 2020 - Ensuring Safe Access to M3P Prescriptions for Patients During COVID-19 Outbreak - The College of Physicians and Surgeons of Manitoba (CPSM), College of Registered Nurses of Manitoba (CRNM) and the College of Pharmacists of Manitoba (CPhM) have received several inquiries regarding measures to ensure safe patient access to Manitoba Prescribing Practices Program (M3P) drugs during the COVID-19 outbreak. Several registrants have also voiced their concern about maintaining safe prescribing practices while implementing social distancing where possible. Inquiries have also been received from prescribers regarding the appropriateness of virtual and phone visits for patients who require a M3P prescription.

    In response to these inquiries, the CPSM, CRNM and CPhM are providing the following guidance when it comes to drugs that usually require an M3P form:


The title RN(NP) is protected under The Regulated Health Professions Act. Its use is restricted to RNs who have met and maintain the requirements for registration on the extended practice register. Click here to read more about the use of regulated professional titles or click here to view the webinar.

Changing Your Information

Complete this form to change your client population

All RN(NP)s are required to provide current employer contact information. To make changes, log in to your online profile using your registration number and password and click the “NP Contact Info” button in the top navigation bar.